Form 8-K - Current report:
SEC Accession No. 0001708599-25-000058
Filing Date
2025-05-22
Accepted
2025-05-22 16:40:16
Documents
14
Period of Report
2025-05-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ser-20250522.htm   iXBRL 8-K 32861
2 EX-3.1 ex31-serinaxcertificateofc.htm EX-3.1 9660
3 EX-99.1 a991-pressreleasexxserinat.htm EX-99.1 7734
  Complete submission text file 0001708599-25-000058.txt   259726

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ser-20250522.xsd EX-101.SCH 1800
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ser-20250522_lab.xml EX-101.LAB 54435
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ser-20250522_pre.xml EX-101.PRE 31811
17 EXTRACTED XBRL INSTANCE DOCUMENT ser-20250522_htm.xml XML 3189
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38519 | Film No.: 25977818
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)